Vemlidy® (Tenofovir Alafenamide) 25 mg 30 tab

Vemlidy® (Tenofovir Alafenamide) 25 mg – Chronic Hepatitis B Treatment

Manufacturer: Gilead Sciences, Inc.

Overview

Vemlidy® is an advanced antiviral medication containing Tenofovir Alafenamide (TAF), developed by Gilead Sciences, USA, for the treatment of chronic hepatitis B (HBV) in adults and adolescents aged 12 years and older.

It is a next-generation formulation of tenofovir that delivers the drug more efficiently to the liver, resulting in lower systemic exposure and reduced kidney and bone toxicity compared to Tenofovir Disoproxil Fumarate (TDF, Viread®).

Composition

• Active ingredient: Tenofovir Alafenamide (TAF)
• Strength: 25 mg

Indications

• Chronic hepatitis B infection in adults and adolescents (≥12 years) with compensated liver disease.

Mechanism of Action

Tenofovir Alafenamide is a nucleotide analog of adenosine monophosphate. It is converted intracellularly into tenofovir diphosphate, which inhibits HBV DNA polymerase, suppressing viral replication.

Dosage and Administration

• Recommended dose: 25 mg once daily, with or without food.
• Treatment duration is determined by a healthcare provider based on viral response.

Benefits

• Highly effective HBV suppression
• Lower renal and bone toxicity versus TDF
• Once-daily dosing
• Excellent tolerability for long-term therapy

Side Effects

Common: headache, fatigue, nausea.
Rare: increased liver enzymes, renal impairment, decreased bone mineral density.

Precautions

• Do not discontinue therapy abruptly (risk of hepatitis flare).
• Monitor renal and hepatic function during treatment.
• Avoid use with strong P-gp inducers (e.g., rifampin).